Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Subjects With Mild to Moderate Hypertension.

Next Previous
X
Search
Trial Profile

A Randomised, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Subjects With Mild to Moderate Hypertension.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Angiotensin inhibitor vaccine (Primary) ; CoVaccineHT
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors BTG; Protherics

    • Most Recent Events

    • 07 Apr 2009 Status changed from recruiting to active, no longer recruiting, as reported in ClinicalTrials.gov record.
    • 02 Apr 2009 Dosing has been suspended for 2-3 months while safety data are reviewed, according to a BTG plc media release.
    • 24 Jun 2008 Blood pressure results are expected in the first half of 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top